Compare Tractor Supply Co (TSCO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tractor Supply Co vs Vertex Pharmaceuticals Incorporated — how do they compare? Tractor Supply Co trades at $33.5 (market cap $16.94B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.6× Tractor Supply Co's market cap, and Tractor Supply Co pays a 2.95% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tractor Supply Co for 88 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TSCO | VRTX | |
|---|---|---|
Market Cap | $16.94B | $128.16B |
Volume | 10,333,598 | 806,603 |
Sector | Consumer Cyclical | Health |
52-Week High | $56.37 | $557.96 |
52-Week Low | $29.14 | $407.37 |
Typical Hold Time | 88 Days | 120 Days |
Enterprise Value | $23.26B | $122.29B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TSCO trades at $33.48, up 3.69% today, with a bullish technical signal from moving averages. The company reported revenue of $15.52B for 2025, with a net income margin of 6.42%, though recent quarters have seen earnings misses. Analyst consensus is a Buy with a $37.00 price target, and the company maintains a 17-year dividend growth streak, with a recent dividend declared for September 2026.
The outlook is mixed; strong fundamentals and dividend history support long-term value, but near-term risks include earnings misses and competitive pressures. The stock offers potential upside to the consensus target, but investors should weigh execution risks against the company's solid market position.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tractor Supply Co
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
